New antibody drug tested to control serious kidney disease
NCT ID NCT05398653
Summary
This study tested a new antibody drug called MIL62 for treating primary membranous nephropathy, a serious autoimmune kidney disease. It compared two doses of MIL62 against an older drug, cyclosporine, in 94 adults. The main goals were to see if MIL62 was safe and if it could help patients achieve remission by reducing harmful antibodies and protein in their urine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Conditions
Explore the condition pages connected to this study.